ELORAC
PharmaELORAC is a pharmaceutical company focused on Oncology, Dermatology, Immunology.
ELORAC's Key Drugs
ELORAC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ELORAC's Recent FDA Approvals
New NDA/BLA approvals for ELORAC over the last two years — novel drugs only, excluding generics and label supplements.
ELORAC's Therapeutic Areas
ELORAC's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ELORAC's Top Competitors
ELORAC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ELORAC Pipeline Snapshot
ELORAC has 3 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1970-07-31
- Latest
- 1998-11-30
- Applications
- 1